

may be made within the scope of the present invention. Accordingly, the present invention is not limited to the specific embodiments as illustrated herein, but is only limited by the following claims.

1. A method of treating, preventing, inhibiting, or reducing a seizure, status epilepticus, neuropathogenesis, or a neuropathology caused by exposure to an organophosphate compound in a subject in need thereof which comprises administering to the subject Pro-2-PAM, a huperzine compound, or both.

2. The method of claim **1**, wherein Pro-2-PAM or the huperzine compound is administered before, during or after exposure to the organophosphate compound.

3. The method of claim **1**, wherein Pro-2-PAM and the huperzine compound are administered at the same time, different times, or both.

4. The method of claim **1**, wherein the huperzine compound is administered as an enantiopure composition or as a mixture.

5. The method of claim **1**, and further comprising administering 2-PAM, a second huperzine compound, or both.

6. The method of claim **5**, wherein the second huperzine compound is -HupA.

7. The method of claim **1**, which further comprises administering at least one supplementary active compound selected from the group consisting of anticholinergics, anticonvulsants, carbamates, benzodiazepines, antiepileptics, barbituates, anesthetics, and oximes.

8. The method of claim **1**, wherein the seizure is a SE causing seizure.

9. A kit which comprises Pro-2-PAM and the huperzine compound packaged together.

10. The kit of claim **9**, further comprising at least one device for delivering Pro-2-PAM, the huperzine compound, or both to a subject.

11. The kit of claim **10**, wherein the device is an autoinjector.

12. The kit of claim **11**, wherein the autoinjector comprises a first compartment containing Pro-2-PAM and a second compartment containing the huperzine compound.

13. The kit according to claim **9**, wherein Pro-2-PAM, the huperzine compound, or both are provided as a single dose or multiple doses.

14. The kit according to claim **9**, wherein Pro-2-PAM and the huperzine compound are provided in therapeutically effective amounts.

15. A composition comprising Pro-2-PAM and the huperzine compound.

16. The composition of claim **15**, wherein the composition comprises Pro-2-PAM and the huperzine compound in therapeutically effective amounts.

17. The composition of claim **16**, wherein the therapeutically effective amounts are amounts which treat, prevent, inhibit, or reduce a seizure, an SE causing seizure, status epilepticus, neuropathogenesis, or a neuropathology caused by exposure to an organophosphate compound.

18. The method of claim **1**, wherein the huperzine compound is a huperzine A compound, preferably +HupA.

19-22. (canceled)

* * * * *